))
ETI (CFTR Triple Therapy): Clinical Opportunities
Manage episode 341189922 series 2902538
Content provided by eCysticFibrosis Review and ECysticFibrosis Review. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by eCysticFibrosis Review and ECysticFibrosis Review or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The advent of triple CFTR modulator therapy – ETI (elexacaftor/tezacaftor/ivacaftor) — poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to ensure their patients get maximum benefit?
Join us as we explore these questions with guest author Professor Edward McKone MD, from St. Vincent’s University Hospital and University College Dublin School of Medicine, in this eCysticFibrosis Review podcast.
Take our post-test to claim CME credits.
Read this podcast's companion newsletter here.
Hosted on Acast. See acast.com/privacy for more information.
72 episodes
Share
